MX2020002596A - Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. - Google Patents

Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.

Info

Publication number
MX2020002596A
MX2020002596A MX2020002596A MX2020002596A MX2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A MX 2020002596 A MX2020002596 A MX 2020002596A
Authority
MX
Mexico
Prior art keywords
cell modulatory
multimeric
methods
cell
modulatory polypeptides
Prior art date
Application number
MX2020002596A
Other languages
English (en)
Inventor
Ronald D Ill Seidel
Rodolfo J Chaparro
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of MX2020002596A publication Critical patent/MX2020002596A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Abstract

La presente descripción proporciona polipéptidos multiméricos moduladores de linfocitos T que comprenden un polipéptido inmunomodulador que presenta una afinidad de unión reducida a un polipéptido coinmunomodulador análogo. Un polipéptido multimérico modulador de linfocitos T es útil para modular la actividad de un linfocito T y para modular una respuesta inmunitaria en un individuo.
MX2020002596A 2017-09-07 2018-09-06 Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. MX2020002596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555499P 2017-09-07 2017-09-07
PCT/US2018/049756 WO2019051091A1 (en) 2017-09-07 2018-09-06 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
MX2020002596A true MX2020002596A (es) 2020-07-20

Family

ID=65634643

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002596A MX2020002596A (es) 2017-09-07 2018-09-06 Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.

Country Status (13)

Country Link
US (3) US20200148744A1 (es)
EP (1) EP3678691A4 (es)
JP (1) JP2020533273A (es)
KR (1) KR20200040860A (es)
CN (1) CN111050793A (es)
AU (1) AU2018328280A1 (es)
BR (1) BR112020004535A2 (es)
CA (1) CA3070484A1 (es)
EA (1) EA202090471A1 (es)
IL (2) IL297361B1 (es)
MX (1) MX2020002596A (es)
TW (1) TW201920248A (es)
WO (1) WO2019051091A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505591B2 (en) * 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970060A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118A4 (en) 2017-03-15 2021-04-07 Cue Biopharma, Inc. PROCESSES FOR MODULATING AN IMMUNE RESPONSE
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20200064085A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3719033A1 (en) 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
US11692020B2 (en) 2019-11-20 2023-07-04 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
CN115297881A (zh) * 2020-03-18 2022-11-04 Gi 医诺微新 包含含有il-2蛋白和cd80蛋白的融合蛋白和抗癌药物的用于治疗癌症的药物组合物
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CN115605494A (zh) * 2020-05-12 2023-01-13 株式会社Lg化学（Kr） 多聚体t细胞调节多肽及其使用方法
WO2022015880A2 (en) * 2020-07-14 2022-01-20 Cue Biopharma, Inc. T-cell modulatory polypeptides with conjugation sites and methods of use thereof
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
WO2023167947A2 (en) * 2022-03-01 2023-09-07 Crosslink Therapeutics Inc. Atp-dependent agonists of immune cells function as anticancer agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US20170176435A1 (en) * 2014-01-21 2017-06-22 Albert Einstein College Of Medicine, Inc. Cellular platform for rapid and comprehensive t-cell immunomonitoring
CN113248623A (zh) * 2014-06-18 2021-08-13 阿尔伯特爱因斯坦医学院 Syntac多肽及其用途

Also Published As

Publication number Publication date
IL272085B2 (en) 2023-03-01
IL297361B1 (en) 2024-03-01
IL272085B (en) 2022-11-01
IL272085A (en) 2020-03-31
AU2018328280A1 (en) 2020-02-13
CA3070484A1 (en) 2019-03-14
TW201920248A (zh) 2019-06-01
BR112020004535A2 (pt) 2020-09-08
EP3678691A4 (en) 2021-06-09
JP2020533273A (ja) 2020-11-19
EP3678691A1 (en) 2020-07-15
US20220119483A1 (en) 2022-04-21
EA202090471A1 (ru) 2020-06-10
US20240025964A1 (en) 2024-01-25
IL297361A (en) 2022-12-01
WO2019051091A1 (en) 2019-03-14
KR20200040860A (ko) 2020-04-20
US20200148744A1 (en) 2020-05-14
CN111050793A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
MX2020002596A (es) Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
MX2021014476A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
EP3679064A4 (en) T-CELL-MODULATING MULTIMERAL POLYPEPTIDE WITH CONJUGATION SITES AND METHOD FOR USING THEREOF
EP3600356A4 (en) ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
MX2021007287A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
MX2019007611A (es) Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
IL262606A (en) pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
NZ756763A (en) Engineered transferrin receptor binding polypeptides
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
MY191944A (en) Binding proteins and methods of use thereof
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2021007479A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
EP3565829A4 (en) MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
WO2018027039A8 (en) COMPOSITIONS AND METHODS FOR MODULATING LAIR SIGNAL TRANSDUCTION
AU2016335217A8 (en) Antigen receptors and uses thereof
SG11202005147WA (en) Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
IL268768A (en) Proteins binding gd2, nkg2d and cd16
AU2015279552A8 (en) Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
WO2015166105A3 (en) Ion channel modulators and uses thereof
EP3445394A4 (en) ALK7 BINDING PROTEINS AND USES THEREOF
IL272374A (en) NKG2D, CD16, and FLT3 binding proteins
WO2018174668A3 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
NZ731491A (en) Cd83 binding proteins and uses thereof